



## **Mylan Announces Appointment of Harry A. Korman as President, North America**

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Harry A. (Hal) Korman to the position of President, North America following the completion of the acquisition of Merck Generics Group today.

In his new role, Mr. Korman will continue to drive growth and development of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the U.S. In addition, he will oversee GenPharm, Inc., the former Canadian subsidiary of Merck Generics and the fourth largest generics company in Canada, and UDL Laboratories, Inc., the U.S. leader in unit dose packaging.

Mr. Korman previously served as President of MPI, as well as Senior Vice President of Mylan Laboratories Inc. Since joining Mylan through its acquisition of UDL Laboratories in 1996, he has served the Company in several capacities of increasing responsibility, including President of UDL and Vice President of Sales and Marketing for MPI.

Mylan Vice Chairman and CEO Robert J. Coury commented: "Hal has played a critical role in our success to date and is a key member of our management team. He has been instrumental in building Mylan into the leader in quality generics in the U.S. that we are today. Since Hal's appointment as President of MPI, he has proven his ability to meet or exceed every objective set for him and he will certainly rise to these new responsibilities. By bringing these North American businesses together under Hal's leadership, we will be best placed to identify and execute on growth and synergy opportunities in the region. I am confident that we will continue to go from strength to strength in North America."

Mr. Korman said: "It's been an honor to be part of Mylan for the last 20 years as the company has grown from a leader in the U.S. to a new global leader in generics and specialty pharmaceuticals. I am also proud to be part of a management team that truly shares one vision for the new Mylan. As we look ahead to the future, there have never been greater opportunities to take the company forward and continue to provide the best quality products and service to our customers."

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit <http://www.mylan.com/>.

SOURCE: Mylan Inc.

CONTACT: Kris King, Mylan, Inc., +1-724-514-1800

Web site: <http://www.mylan.com/>